DANYELZA NAXITAMAB

Serial Number 88749157
Registration 6214682
700

Registration Progress

Application Filed
Jan 7, 2020
Under Examination
Approved for Publication
Sep 22, 2020
Published for Opposition
Sep 22, 2020
Registered
Dec 8, 2020

Attorney Assistance

Section 8 Declaration Due (Principal Register) (Based on registration date 20201208)
Due: Dec 08, 2026 341 days

Trademark Image

DANYELZA NAXITAMAB

Basic Information

Serial Number
88749157
Registration Number
6214682
Filing Date
January 7, 2020
Registration Date
December 8, 2020
Published for Opposition
September 22, 2020
Drawing Code
3

Status Summary

Current Status
Active
Status Code
700
Status Date
Dec 8, 2020
Registration
Registered
Classes
005 042

Rights Holder

Y-mAbs Therapeutics, Inc

03
Address
230 Park Avenue, Suite 3350
New York, NY 10169

Ownership History

Y-mAbs Therapeutics, Inc

Original Applicant
03
New York, NY

Y-mAbs Therapeutics, Inc

Owner at Publication
03
New York, NY

Y-mAbs Therapeutics, Inc

Original Registrant
03
New York, NY

Legal Representation

Attorney
Andrew N. Spivak

USPTO Deadlines

Next Deadline
341 days remaining
Section 8 Declaration Due (Principal Register) (Based on registration date 20201208)
Due Date
December 08, 2026
Grace Period Ends
June 08, 2027
Additional deadlines exist. Contact your attorney for complete deadline information.

Application History

34 events
Date Code Type Description Documents
Dec 8, 2025 REM1 E COURTESY REMINDER - SEC. 8 (6-YR) E-MAILED Loading...
Dec 8, 2020 R.PR A REGISTERED-PRINCIPAL REGISTER Loading...
Sep 22, 2020 NPUB E OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED Loading...
Sep 22, 2020 PUBO A PUBLISHED FOR OPPOSITION Loading...
Sep 2, 2020 NONP E NOTIFICATION OF NOTICE OF PUBLICATION E-MAILED Loading...
Aug 19, 2020 CNSA O APPROVED FOR PUB - PRINCIPAL REGISTER Loading...
Aug 18, 2020 TEME I TEAS/EMAIL CORRESPONDENCE ENTERED Loading...
Aug 18, 2020 CRFA I CORRESPONDENCE RECEIVED IN LAW OFFICE Loading...
Aug 18, 2020 TROA I TEAS RESPONSE TO OFFICE ACTION RECEIVED Loading...
Jul 21, 2020 GNRN O NOTIFICATION OF NON-FINAL ACTION E-MAILED Loading...
Jul 21, 2020 GNRT O NON-FINAL ACTION E-MAILED Loading...
Jul 21, 2020 CNRT R NON-FINAL ACTION WRITTEN Loading...
Jul 20, 2020 ZZZX Z PREVIOUS ALLOWANCE COUNT WITHDRAWN Loading...
Jun 23, 2020 PBCR Z WITHDRAWN FROM PUB - OG REVIEW QUERY Loading...
Jun 10, 2020 FIXD O ELECTRONIC RECORD REVIEW COMPLETE Loading...
Jun 5, 2020 ERRR O ON HOLD - ELECTRONIC RECORD REVIEW REQUIRED Loading...
Jun 2, 2020 CNSA O APPROVED FOR PUB - PRINCIPAL REGISTER Loading...
Jun 2, 2020 TEME I TEAS/EMAIL CORRESPONDENCE ENTERED Loading...
Jun 2, 2020 CRFA I CORRESPONDENCE RECEIVED IN LAW OFFICE Loading...
May 27, 2020 ERSI I TEAS RESPONSE TO SUSPENSION INQUIRY RECEIVED Loading...
May 11, 2020 GNS3 O NOTIFICATION OF LETTER OF SUSPENSION E-MAILED Loading...
May 11, 2020 GNSL S LETTER OF SUSPENSION E-MAILED Loading...
May 11, 2020 CNSL R SUSPENSION LETTER WRITTEN Loading...
May 8, 2020 TEME I TEAS/EMAIL CORRESPONDENCE ENTERED Loading...
May 8, 2020 CRFA I CORRESPONDENCE RECEIVED IN LAW OFFICE Loading...
May 7, 2020 ALIE A ASSIGNED TO LIE Loading...
May 4, 2020 TROA I TEAS RESPONSE TO OFFICE ACTION RECEIVED Loading...
Mar 26, 2020 GNRN O NOTIFICATION OF NON-FINAL ACTION E-MAILED Loading...
Mar 26, 2020 GNRT F NON-FINAL ACTION E-MAILED Loading...
Mar 26, 2020 CNRT R NON-FINAL ACTION WRITTEN Loading...
Mar 26, 2020 DOCK D ASSIGNED TO EXAMINER Loading...
Jan 11, 2020 MDSC E NOTICE OF DESIGN SEARCH CODE E-MAILED Loading...
Jan 10, 2020 NWOS I NEW APPLICATION OFFICE SUPPLIED DATA ENTERED Loading...
Jan 10, 2020 NWAP I NEW APPLICATION ENTERED Loading...

Detailed Classifications

Class 005
Pharmaceutical preparations and substances for the treatment of cancer; Pharmaceutical preparations and substances for the prevention of cancer
Class 042
Research and development services in the field of antibodies; research and development services in the field of antibody technology; laboratory research and analysis services relating to the production of antibodies; scientific and technological services, namely, scientific research, analysis, and testing in the field of antibodies, and research and design relating thereto; industrial analysis and research services in the field of antibodies

Additional Information

Design Mark
The mark consists of the stylized, capitalized, teal word "DANYELZA" with three stacked V-shapes emanating from the top of the letter "Y", with the first in purple, the second in light green, and the third in the same teal color. Left-justified beneath the word "DANYELZA", in all lower-case letters and in a different font, is the word "NAXITAMAB" in gray.
Color Claim
The color(s) teal, purple, light green, and gray is/are claimed as a feature of the mark.

Classification

International Classes
005 042

Disclaimers

The following terms have been disclaimed and are not claimed as part of the trademark:
Specific Disclaimer
"NAXITAMAB"